Prognostic significance of the cell cycle inhibitor p27(Kip1) in acute myeloid leukemia

T. Yokozawa, M. Towatari, H. Iida, K. Takeyama, M. Tanimoto, H. Kiyoi, T. Motoji, N. Asou, K. Saito, M. Takeuchi, Y. Kobayashi, S. Miyawaki, Y. Kodera, R. Ohno, H. Saito, T. Naoe

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

There are few molecular biologic determinants that are prognostic for patients with acute myeloid leukemia (AML). Hence, we examined whether cellular levels of the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia could be used to predict clinical outcome in AML. Using immunoblot analysis, levels of p27 were assessed in blast cells from 72 AML patients who were registered and treated by the identical chemotherapy protocol. AML cases were classified into three groups on the basis of the percentage of the expression level of p27 compared to a control cell line. AML cases exhibiting p27 expression at low, moderate, and high levels were 43, 9, and 20 cases, respectively. No significant differences in the rates of complete remission (CR) were observed among the three groups. Although the level of p27 expression was not correlated with any other possible prognostic markers, such as age, white blood cell count, chromosome abnormalities, and FAB subclasses, patients with high p27 expression had a significantly increased disease-free survival (DFS) (78 vs 19, P = 0.004). We further examined the expression of cyclin E at the protein level in all 72 AML cases. We observed a statistically significant correlation between a high cyclin E level and a high p27 level (P <0.005). However, we failed to find any correlation between the rates of CR or DFS and cyclin E expression. The present study reveals that levels of p27 expression can be one of the useful prognostic molecular markers for AML.

Original languageEnglish
Pages (from-to)28-33
Number of pages6
JournalLeukemia
Volume14
Issue number1
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Cell Cycle
Cyclin E
Disease-Free Survival
Cyclin-Dependent Kinase Inhibitor p27
Leukocyte Count
Chromosome Aberrations
Drug Therapy
Cell Line
Proteins

Keywords

  • AML
  • Cyclin-dependent kinase inhibitor
  • p27
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Yokozawa, T., Towatari, M., Iida, H., Takeyama, K., Tanimoto, M., Kiyoi, H., ... Naoe, T. (2000). Prognostic significance of the cell cycle inhibitor p27(Kip1) in acute myeloid leukemia. Leukemia, 14(1), 28-33.

Prognostic significance of the cell cycle inhibitor p27(Kip1) in acute myeloid leukemia. / Yokozawa, T.; Towatari, M.; Iida, H.; Takeyama, K.; Tanimoto, M.; Kiyoi, H.; Motoji, T.; Asou, N.; Saito, K.; Takeuchi, M.; Kobayashi, Y.; Miyawaki, S.; Kodera, Y.; Ohno, R.; Saito, H.; Naoe, T.

In: Leukemia, Vol. 14, No. 1, 2000, p. 28-33.

Research output: Contribution to journalArticle

Yokozawa, T, Towatari, M, Iida, H, Takeyama, K, Tanimoto, M, Kiyoi, H, Motoji, T, Asou, N, Saito, K, Takeuchi, M, Kobayashi, Y, Miyawaki, S, Kodera, Y, Ohno, R, Saito, H & Naoe, T 2000, 'Prognostic significance of the cell cycle inhibitor p27(Kip1) in acute myeloid leukemia', Leukemia, vol. 14, no. 1, pp. 28-33.
Yokozawa T, Towatari M, Iida H, Takeyama K, Tanimoto M, Kiyoi H et al. Prognostic significance of the cell cycle inhibitor p27(Kip1) in acute myeloid leukemia. Leukemia. 2000;14(1):28-33.
Yokozawa, T. ; Towatari, M. ; Iida, H. ; Takeyama, K. ; Tanimoto, M. ; Kiyoi, H. ; Motoji, T. ; Asou, N. ; Saito, K. ; Takeuchi, M. ; Kobayashi, Y. ; Miyawaki, S. ; Kodera, Y. ; Ohno, R. ; Saito, H. ; Naoe, T. / Prognostic significance of the cell cycle inhibitor p27(Kip1) in acute myeloid leukemia. In: Leukemia. 2000 ; Vol. 14, No. 1. pp. 28-33.
@article{47b00f77d78043639dad4fc38973c668,
title = "Prognostic significance of the cell cycle inhibitor p27(Kip1) in acute myeloid leukemia",
abstract = "There are few molecular biologic determinants that are prognostic for patients with acute myeloid leukemia (AML). Hence, we examined whether cellular levels of the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia could be used to predict clinical outcome in AML. Using immunoblot analysis, levels of p27 were assessed in blast cells from 72 AML patients who were registered and treated by the identical chemotherapy protocol. AML cases were classified into three groups on the basis of the percentage of the expression level of p27 compared to a control cell line. AML cases exhibiting p27 expression at low, moderate, and high levels were 43, 9, and 20 cases, respectively. No significant differences in the rates of complete remission (CR) were observed among the three groups. Although the level of p27 expression was not correlated with any other possible prognostic markers, such as age, white blood cell count, chromosome abnormalities, and FAB subclasses, patients with high p27 expression had a significantly increased disease-free survival (DFS) (78 vs 19, P = 0.004). We further examined the expression of cyclin E at the protein level in all 72 AML cases. We observed a statistically significant correlation between a high cyclin E level and a high p27 level (P <0.005). However, we failed to find any correlation between the rates of CR or DFS and cyclin E expression. The present study reveals that levels of p27 expression can be one of the useful prognostic molecular markers for AML.",
keywords = "AML, Cyclin-dependent kinase inhibitor, p27, Prognosis",
author = "T. Yokozawa and M. Towatari and H. Iida and K. Takeyama and M. Tanimoto and H. Kiyoi and T. Motoji and N. Asou and K. Saito and M. Takeuchi and Y. Kobayashi and S. Miyawaki and Y. Kodera and R. Ohno and H. Saito and T. Naoe",
year = "2000",
language = "English",
volume = "14",
pages = "28--33",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Prognostic significance of the cell cycle inhibitor p27(Kip1) in acute myeloid leukemia

AU - Yokozawa, T.

AU - Towatari, M.

AU - Iida, H.

AU - Takeyama, K.

AU - Tanimoto, M.

AU - Kiyoi, H.

AU - Motoji, T.

AU - Asou, N.

AU - Saito, K.

AU - Takeuchi, M.

AU - Kobayashi, Y.

AU - Miyawaki, S.

AU - Kodera, Y.

AU - Ohno, R.

AU - Saito, H.

AU - Naoe, T.

PY - 2000

Y1 - 2000

N2 - There are few molecular biologic determinants that are prognostic for patients with acute myeloid leukemia (AML). Hence, we examined whether cellular levels of the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia could be used to predict clinical outcome in AML. Using immunoblot analysis, levels of p27 were assessed in blast cells from 72 AML patients who were registered and treated by the identical chemotherapy protocol. AML cases were classified into three groups on the basis of the percentage of the expression level of p27 compared to a control cell line. AML cases exhibiting p27 expression at low, moderate, and high levels were 43, 9, and 20 cases, respectively. No significant differences in the rates of complete remission (CR) were observed among the three groups. Although the level of p27 expression was not correlated with any other possible prognostic markers, such as age, white blood cell count, chromosome abnormalities, and FAB subclasses, patients with high p27 expression had a significantly increased disease-free survival (DFS) (78 vs 19, P = 0.004). We further examined the expression of cyclin E at the protein level in all 72 AML cases. We observed a statistically significant correlation between a high cyclin E level and a high p27 level (P <0.005). However, we failed to find any correlation between the rates of CR or DFS and cyclin E expression. The present study reveals that levels of p27 expression can be one of the useful prognostic molecular markers for AML.

AB - There are few molecular biologic determinants that are prognostic for patients with acute myeloid leukemia (AML). Hence, we examined whether cellular levels of the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia could be used to predict clinical outcome in AML. Using immunoblot analysis, levels of p27 were assessed in blast cells from 72 AML patients who were registered and treated by the identical chemotherapy protocol. AML cases were classified into three groups on the basis of the percentage of the expression level of p27 compared to a control cell line. AML cases exhibiting p27 expression at low, moderate, and high levels were 43, 9, and 20 cases, respectively. No significant differences in the rates of complete remission (CR) were observed among the three groups. Although the level of p27 expression was not correlated with any other possible prognostic markers, such as age, white blood cell count, chromosome abnormalities, and FAB subclasses, patients with high p27 expression had a significantly increased disease-free survival (DFS) (78 vs 19, P = 0.004). We further examined the expression of cyclin E at the protein level in all 72 AML cases. We observed a statistically significant correlation between a high cyclin E level and a high p27 level (P <0.005). However, we failed to find any correlation between the rates of CR or DFS and cyclin E expression. The present study reveals that levels of p27 expression can be one of the useful prognostic molecular markers for AML.

KW - AML

KW - Cyclin-dependent kinase inhibitor

KW - p27

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0033971171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033971171&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 28

EP - 33

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -